Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 20;16(11):e74076.
doi: 10.7759/cureus.74076. eCollection 2024 Nov.

Comparative Effects of Rosuvastatin and Atorvastatin Loading Doses on Immediate Post-percutaneous Coronary Intervention (PCI) Thrombolysis in Myocardial Infarction (TIMI) Flow in ST-Segment Elevation Myocardial Infarction (STEMI) Patients

Ahmed Jamal Chaudhary  1   2 , Sana Iqbal  3 , Nisar Ahmad Khan  4 , Anshaal Furrukh  5 , Shah Bano  6 , Muhammad Nasir Ali  7 , Afaq Ali  8 , Sajjad Ullah Khan  9
Affiliations

Comparative Effects of Rosuvastatin and Atorvastatin Loading Doses on Immediate Post-percutaneous Coronary Intervention (PCI) Thrombolysis in Myocardial Infarction (TIMI) Flow in ST-Segment Elevation Myocardial Infarction (STEMI) Patients

Ahmed Jamal Chaudhary et al. Cureus. .

Abstract

Background: Primary percutaneous coronary intervention (PCI) is crucial in managing acute ST-segment elevation myocardial infarction (STEMI), emphasizing the importance of optimal myocardial reperfusion.

Objective: The goal of this research was to determine how loading doses of rosuvastatin and atorvastatin affected the flow rate of thrombolysis in myocardial infarction (TIMI) immediately post-perfusion thrombolysis in patients undergoing primary PCI.

Methodology: This prospective, comparative study was carried out over a one-year period (January 2023 to December 2023) in Pakistan. Data was gathered from patient interviews and electronic medical records for adult patients receiving primary PCI. Interventional cardiologists who were blinded to the evaluation of the immediate post-perfusion TIMI flow conducted statistical analysis to compare the results between the two statin groups.

Results: Both groups had good procedural success rates: 184 patients (92.00%) in the group using rosuvastatin and 179 patients (89.50%) in the group on atorvastatin (p = 0.284). A comparable use of auxiliary equipment was seen, with 103 patients (51.50%) and 97 patients (48.50%) in the atorvastatin group and 108 patients (54.00%) and 92 patients (46.00%) in the rosuvastatin group, respectively (p = 0.53). There were no notable variations in the immediate post-perfusion TIMI flow grades either, with p-values of 0.532 for normal flow and 0.421 for no-reflow. The two groups' mean lengths of hospital stays were comparable, measuring 3.5 days (± 1.2) for the rosuvastatin group and 3.8 days (± 1.3) for the atorvastatin group (p = 0.321).

Conclusion: Rosuvastatin and atorvastatin had comparable rapid post-perfusion TIMI flows in the initial PCI participants, indicating that they may be used interchangeably to maximize myocardial reperfusion in acute STEMI.

Keywords: atorvastatin; cardiovascular outcomes; myocardial reperfusion; pci; rosuvastatin; stemi.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. IRB of Lahore Medical and Dental College (LMDC) issued approval LM&DC 30656-21/2023. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Comparing adverse events in the groups taking atorvastatin and rosuvastatin
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Comparative Study between safety and efficacy of pharmacoinvasive strategy and primary percutaneous coronary angioplasty in patients presenting by acute ST segment elevation myocardial infarction. Samia M, Ahmed GS, Ayman A, Yasser H. J Cairo Univ. 2019;87:705–712.
    1. Procedural volume and outcomes after primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction in Kerala, India: report of the Cardiological Society of India-Kerala primary percutaneous coronary intervention registry. Jabir A, Mathew A, Zheng Y, et al. J Am Heart Assoc. 2020;9:0. - PMC - PubMed
    1. Acute coronary syndromes (ACS)-unravelling biology to identify new therapies-the microcirculation as a frontier for new therapies in ACS. Vaidya K, Tucker B, Patel S, Ng MK. Cells. 2021;10:2188. - PMC - PubMed
    1. Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection. Singh V, Cohen MG. Curr Treat Options Cardiovasc Med. 2014;16:302. - PubMed
    1. Coronary no-reflow after primary percutaneous coronary intervention-current knowledge on pathophysiology, diagnosis, clinical impact and therapy. Ndrepepa G, Kastrati A. J Clin Med. 2023;12:5592. - PMC - PubMed

LinkOut - more resources